Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pure Bioscience (PURE)

Pure Bioscience (PURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pure Bioscience 771 JAMACHA ROAD #512 EL CAJON CA 92019 USA

www.purebio.com Employees: 12 P: 619-596-8600

Sector:

Medical

INDUSTRY GROUPING:

Medical Products

Description:

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.

Key Statistics

Overview:

Market Capitalization, $K 5,337
Enterprise Value, $K 10,167
Shares Outstanding, K 111,886
Float, K 72,099
% Float 64.44%
Short Interest, K 26
Short Float 0.02%
Days to Cover 1.00
Short Volume Ratio 0.31
% of Insider Shareholders 35.56%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 2,200 K
Annual Net Income, $ -2,400 K
Last Quarter Sales, $ 710 K
Last Quarter Net Income, $ -460 K
EBIT, $ -2,030 K
EBITDA, $ -1,880 K

Growth:

1-Year Return -27.84%
3-Year Return -54.57%
5-Year Return -93.68%
5-Year Revenue Growth -68.21%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 12/15/25
Next Earnings Date 03/16/26
Earnings Per Share ttm -0.03
EPS Growth vs. Prev Qtr 100.00%
EPS Growth vs. Prev Year 100.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 08/15/12

PURE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -377.91%
Profit Margin % -109.09%
Debt/Equity -0.64
Price/Sales 2.13
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.05
Interest Coverage -7.00
60-Month Beta 0.59
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar